Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol

Background

Tramadol is widely used for acute, chronic, and neuropathic pain. Its primary active metabolite is O-desmethyltramadol (M1), which is mainly accountable for the μ-opioid receptor-related analgesic effect. Tramadol is metabolized to M1 mainly by cytochrome P450 (CYP)2D6 enzyme and to other metabolites by CYP3A4 and CYP2B6. We investigated the possible interaction of tramadol with the antifungal agents terbinafine (CYP2D6 inhibitor) and itraconazole (CYP3A4 inhibitor).

Methods

We used a randomized placebo-controlled crossover study design with 12 healthy subjects, of which 8 were extensive and 4 were ultrarapid CYP2D6 metabolizers. On the pretreatment day 4 with terbinafine (250 mg once daily), itraconazole (200 mg once daily) or placebo, subjects were given tramadol 50 mg orally. Plasma concentrations of tramadol and M1 were determined over 48 h and some pharmacodynamic effects over 12 h. Pharmacokinetic variables were calculated using standard non-compartmental methods.

Results

Terbinafine increased the area under plasma concentration–time curve (AUC_0-∞) of tramadol by 115 % and decreased the AUC_0-∞ of M1 by 64 % (P?<?0.001). Terbinafine increased the peak concentration (C _max) of tramadol by 53 % (P?<?0.001) and decreased the C _max of M1 by 79 % (P?<?0.001). After terbinafine pretreatment the elimination half-life of tramadol and M1 were increased by 48 and 50 %, respectively (P?<?0.001). Terbinafine reduced subjective drug effect of tramadol (P?<?0.001). Itraconazole had minor effects on tramadol pharmacokinetics.

Conclusions

Terbinafine may reduce the opioid effect of tramadol and increase the risk of its monoaminergic adverse effects. Itraconazole has no meaningful interaction with tramadol in subjects who have functional CYP2D6 enzyme.